CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to HNPHY

Gemcitabine combined with docetaxel

Phase 3
Hansoh Pharmaceutical Group Co Limited/ADR (HNPHY)

Phase 3

Development Phase

0

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Development History
Aug '26
HNPHYPhase 3
Positive

Gemcitabine combined with docetaxel Phase 3 Est. Readout

Gemcitabine combined with docetaxel
Aug 2026~
CT.gov
Competitive Landscape

1 competitor in Osteosarcoma

View Full Landscape
Drug Information

Target Indication

Osteosarcoma

Clinical Trial

NCT06935409

Last updated: 4/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.